Enable JavaScript to visit this website.

How is ELELYSO made?

Main content

How is ELELYSO made?

ELELYSO® (taliglucerase alfa) for injection is made by the Israeli biotherapeutics company Protalix.

Hero Image: 

First-of-its-kind technology

ELELYSO is made with first-of-its-kind technology called the ProCellEx®* expression system, using plant cells (from carrots).

WATCH: How ELELYSO is made

Here are some features of plant cell-based technology:

ELELYSO is plant based

ELELYSO is made by growing the enzyme glucocerebrosidase inside carrot cells. The growth medium used is made from sucrose, vitamins, minerals, and water.

Production is expandable

ELELYSO is also made at a dedicated manufacturing site. The plant cell-based production system uses multiple 800-liter disposable bioreactors (the vats that ELELYSO is made in). Bioreactors can be easily added to increase ELELYSO supply as needed.

Active enzyme molecules

These enzymes are naturally able to enter Gaucher cells without any chemical alterations. These enzymes naturally have a uniform structure that is reproducible and consistent from batch to batch.

Pfizer’s Supply Continuity Program

To help minimize issues with the supply of ELELYSO, Pfizer plans to continue maintaining a rolling 24 months of supply at various stages of production around the world for US patients prescribed ELELYSO. Pfizer regularly verifies patient demand as part of the monthly planning process for ELELYSO and can rapidly scale production. The program was developed to help fill a need within the Gaucher community.

*ProCellEx is a registered trademark of Protalix Biotherapeutics.

Protalix: an Israeli-based biotechnology company

Even though Gaucher disease is a rare disease, it is familiar to the employees of Protalix Biotherapeutics, an Israeli-based biotech company. Several have family members and friends who have personal experience with Gaucher disease, so the employees truly understand the impact it can have on patients and their families. Out of their passion to help people, ELELYSO was developed as a treatment for Type 1 Gaucher disease.

*ProCellEx is a registered trademark of Protalix Biotherapeutics.

Footer content